Shares of Vital Therapies Inc (NASDAQ:VTL) shot up 10% on Thursday . The stock traded as high as $0.23 and last traded at $0.22. 1,672,081 shares were traded during trading, an increase of 26% from the average session volume of 1,331,694 shares. The stock had previously closed at $0.20.
Several research firms have recently weighed in on VTL. ValuEngine lowered shares of Vital Therapies from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research lowered shares of Vital Therapies from a “buy” rating to a “hold” rating in a report on Saturday, November 17th. Seven investment analysts have rated the stock with a hold rating, The company has an average rating of “Hold” and an average target price of $12.00.
The firm has a market cap of $8.45 million, a price-to-earnings ratio of -0.17 and a beta of 3.65.
Several institutional investors have recently modified their holdings of VTL. Bank of New York Mellon Corp increased its holdings in shares of Vital Therapies by 163.8% in the second quarter. Bank of New York Mellon Corp now owns 87,942 shares of the company’s stock valued at $602,000 after purchasing an additional 54,611 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in shares of Vital Therapies in the second quarter valued at approximately $388,000. BlackRock Inc. increased its holdings in shares of Vital Therapies by 134.8% in the second quarter. BlackRock Inc. now owns 2,242,025 shares of the company’s stock valued at $15,356,000 after purchasing an additional 1,287,310 shares in the last quarter. Vanguard Group Inc increased its holdings in shares of Vital Therapies by 11.1% in the third quarter. Vanguard Group Inc now owns 1,481,908 shares of the company’s stock valued at $408,000 after purchasing an additional 148,016 shares in the last quarter. Finally, Virtu Financial LLC increased its holdings in shares of Vital Therapies by 120.3% in the fourth quarter. Virtu Financial LLC now owns 310,499 shares of the company’s stock valued at $58,000 after purchasing an additional 169,530 shares in the last quarter. 20.60% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4116308/vital-therapies-vtl-shares-up-10.html.
About Vital Therapies (NASDAQ:VTL)
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
See Also: Short Selling
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.